Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11943476 | 0.92 | RBP4 (0.47) | LMNASMN1; SMN2MAPTALDH1A1DCTPP1 | |
| SCHEMBL11943389 | 0.92 | KMT2A (0.49) | LMNASMN1; SMN2RAB9AMAPTALDH1A1 | |
| SCHEMBL11943474 | 0.85 | FAAH (0.49) | SMN1; SMN2MAPTALDH1A1DCTPP1RXFP1 | |
| SCHEMBL11943473 | 0.84 | ALDH1A1 (0.49) | MAPTALDH1A1DCTPP1RXFP1HTT | |
| SCHEMBL11943385 | 0.82 | NPC1 (0.46) | LMNASMN1; SMN2RAB9AMAPTALDH1A1 | |
| SCHEMBL11943394 | 0.81 | ALDH1A1 (0.51) | LMNASMN1; SMN2RAB9AMAPTALDH1A1 | |
| SCHEMBL11943428 | 0.80 | SMO (0.44) | LMNASMN1; SMN2RAB9AMAPTALDH1A1 | |
| SCHEMBL11943391 | 0.80 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2MAPTALDH1A1DCTPP1 | |
| SCHEMBL11943383 | 0.80 | ALDH1A1 (0.49) | LMNASMN1; SMN2RAB9AMAPTALDH1A1 | |
| SCHEMBL11943382 | 0.80 | MAPT (0.56) | LMNASMN1; SMN2RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | SCHERING CORPORATION (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158992-A1 | PIPERAZINE-SUBSTITUTED PYRIDAZINONE DERIVATIVES USEFUL AS GLUCAN SYNTHASE INHIBITORS | DPM1, GMPS, MAN2A1 | LMNA 1760/4885SMN1; SMN2 3332/4885RAB9A 4434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.